Skip to main content
Clinical Trials/NCT00687232
NCT00687232
Completed
Phase 1

A Randomised, Placebo-controlled Single-blind, Single-centre Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

AstraZeneca1 site in 1 country30 target enrollmentJanuary 2008
ConditionsHealthy
InterventionsAZD4818Placebo

Overview

Phase
Phase 1
Intervention
AZD4818
Conditions
Healthy
Sponsor
AstraZeneca
Enrollment
30
Locations
1
Primary Endpoint
Incidence and nature of adverse Event, 12-lead ECG, BP, pulse rate, body temperature, spirometry
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

The purpose is to investigate safety and tolerability of single and multiple ascending inhaled doses of AZD4818 in healthy Japanese male volunteers.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
May 2008
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Provision of informed consent
  • Body Mass Index (BMI) between 18.0-27.0 kg/m2
  • No clinically relevant abnormal findings

Exclusion Criteria

  • Acute illness which requires medical intervention
  • Definite or suspected personal history of adverse drug reactions or drug hypersensitivity.
  • Clinical relevant disease or disorder (past or present)
  • A history of respiratory disorders

Arms & Interventions

1

AZD4818

Intervention: AZD4818

2

Intervention: Placebo

Outcomes

Primary Outcomes

Incidence and nature of adverse Event, 12-lead ECG, BP, pulse rate, body temperature, spirometry

Time Frame: During the study

Lab assessment

Time Frame: During the study

Secondary Outcomes

  • Pharmacokinetics(During the study)

Study Sites (1)

Loading locations...

Similar Trials